Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline Post ContentamlxRead More You might also be interested in reading Hong Kong-based Chiron Partners launches $50M Terra fund. August 8, 2025 In Mainstream ← Previous post Next post →